Grass pollen-specific immunoglobulin E (sIgE)

Grass pollen-specific immunoglobulin E (IgE) antibodies are specialized glycoproteins produced by the immune system in response to proteins found in grass pollens, such as those from Timothy grass (Phleum pratense) [PMID: 29101900]. These antibodies are the primary mediators of Type I hypersensitivity reactions, which manifest clinically as seasonal allergic rhinitis (hay fever) and allergic asthma [PMID: 30143150]. Upon re-exposure to grass pollen, the allergens cross-link IgE molecules bound to high-affinity FcεRI receptors on the surface of mast cells and basophils, triggering the immediate release of inflammatory mediators like histamine and leukotrienes [StatPearls: NBK537020]. In the pharmaceutical context, these antibodies are targeted by monoclonal antibodies like Omalizumab, which sequesters free IgE to prevent receptor binding, and by allergen-specific immunotherapy (AIT), which aims to induce immunological tolerance and shift the antibody profile from IgE to protective IgG4 [PMID: 28434611]. Monitoring the levels of these specific antibodies is crucial for diagnosing allergies and assessing the efficacy of desensitization treatments [PMID: 31603548].

Other names

Grass pollen-specific IgE antibodiesGrass pollen sIgEAnti-grass pollen IgEAllergen-specific IgE (grass)

Omalizumab binds to the Cε3 domain of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils [FDA Label]. Allergen immunotherapy (AIT) works by inducing regulatory T cells and promoting the production of allergen-specific IgG4 blocking antibodies that compete with IgE for allergen binding, thereby inhibiting the allergic cascade [PMID: 30143150].